FAIRFIELD, N.J., July 17 Arno Therapeutics, Inc.(OTC Bulletin Board: ARNI), today announced that its stock ticker symbol onthe OTC Bulletin Board has changed from "LRRI.OB" to "ARNI.OB" effective July17, 2008.
About Arno Therapeutics
Arno Therapeutics, Inc. is a clinical-stage biopharmaceutical company thatdevelops and commercializes innovative products for the treatment of cancerpatients. Arno's lead compound is AR-67, a novel, third-generationcamptothecin analogue in Phase I studies in patients with advanced solidtumors that has demonstrated high potency and significantly improvedpharmacokinetic properties when compared with marketed second-generationproducts in its class. Arno is also developing two pre-clinical compounds. AR-12 is a potential first-in-class, orally available PI3-k/Akt inhibitorundergoing IND-enabling studies. AR-42 is an orally available, targetedinhibitor of the Pan-DAC and Akt pathways also undergoing IND-enablingstudies. Arno is actively pursuing additional compounds to expand itsportfolio. For more information on Arno please visit www.arnothera.com.
This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995 that involvesubstantial risks and uncertainties. All statements, other than statements ofhistorical facts, included in this press release regarding our strategy,future operations, outlook, milestones, the success of Arno's productdevelopment, future financial position, future financial results, plans andobjectives of management are forward-looking statements. We may not actuallyachieve these plans, intentions or expectations and Arno cautions investorsnot to place undue reliance on our forward-looking statements. Actual resultsor events could differ materially from the plans, intentions and expectationsdisclosed in the forward-looking statements we make. Various important factorsthat could cause actual results or events to differ materially from theforward-looking statements that we make are described in greater detail in thereports we file with Securities and Exchange Commission, including thosedescribed under the caption "Risk Factors" in our Current Report on Form 8-Kfiled with the Securities and Exchange Commission on June 9, 2008. Arno isproviding this information as of the date of this press release and does notundertake any obligation to update any forward-looking statements as a resultof new information, future events or otherwise.
SOURCE Arno Therapeutics, Inc.